Ligand Pharmaceuticals, Inc. US:LGND (NASDAQ NATIONAL MARKET)

• Exchange: NASDAQ NATIONAL MARKET
• Sector: Healthcare
• Industry: Drugs - Generic
• Market Cap: Mid (654.2M)
• Inst. Ownership: 79.68%
• Full Time Employees: 21
• Next Earnings: 8/9/2013

• News
• Officers & Directors
• Sec. Fillings
• Insider Trading
• Headlines

Ligand Pharmaceuticals, Inc., is incorporated in Delaware. It is a biopharmaceutical company engaged in developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. With its portfolio of assets across numerous technology types, therapeutic areas, drug targets, and industry partners, the Company offers investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. The Company has portfolio of over 80 current and future potential revenue generating programs, over 70 of which are fully funded by its partners. It has multiple partnered programs in its portfolio that are either in or nearing the regulatory approval process. GSK’s Promacta® (Eltrombopag) is the first oral thrombopoietin (TPO) receptor agonist therapy for the treatment of adult patients with chronic immune (idiopathic) thrombocytopenic purpura, or ITP. In 2010, GSK received approval for Revolade® (eltrombopag/Promacta) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) and from the Japanese Ministry of Health, Labour and Welfare for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic ITP. The Company currently receives royalty revenues from Pfizer, Inc., or Pfizer, for sales of the pain therapeutic Avinza®. In 2010, its partner Pfizer launched Viviant® (bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis. The drug is also marketed in Spain under the brand name Conbriza® through a co-promotion with Almirall, an international pharmaceutical company based in Spain. In 2006, Ligand outlicensed Nexterone, an injectable formulation combining amiodarone and Captisol, to Baxter International, or Baxter (formerly Prism Pharmaceuticals, Inc.). In 2010, its partner Pfizer launched Viviant (bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis. The Company currently has no manufacturing facilities and rely on third parties, including its collaborative partners, for clinical production of any products or compounds. Its competitive position also depends upon its ability to attract and retain qualified personnel, obtain patent protection or otherwise develop proprietary products or processes, and secure sufficient capital resources for the often substantial period between technological conception and commercial sales. The Company is subject to rigorous regulation by federal and various state authorities, including the FDA.

• MSN profile
• Yahoo profile
• Google profile
• Market Intelligence
• ZACKS profile
• Reuter profile
• Business Week
• Morningstar

Growth Grade

Historical Growth Grade:

F (14.61)

YOY Growth Grade:

F (13.79)

Click on buttons above for detailed yearly growth rates.

Market Ratios

• Dividend Yield:

• Beta: 1.16

  Beta of 1.16 suggests that the stock is volatile as the rest of the market (fairly priced).

• PE: -1,000.00

• EP: -0.1%

• PEG:

  PEG Ratio of suggests that

• PEGY:

  PEGY Ratio of suggests that

• Price/BVPS: 22.55

Profitability Ratios

• ROS: -3.4%

  The value of this ratio depends on the business and/or industry. Usually the higher ratio the better.

• ROA: -3.7%

  Low ratio usually means poor performance, or ineffective use of assets by management. High ratio usually means good performance.

• ROI: -14.6%

  ROI of -14.6% suggests that a company may not be able to fund future growth from within.

• ROIC: -0.3%

  ROIC of -0.3% suggests that a company may not be able to fund future growth from within.

Liquidity Ratios

• Current Ratio: 0.67

  Current Ratio of 0.67 suggests that a company may not be able to pay off bills as rapidly as it should.

• Quick Ratio: 0.48

  Quick Ratio of 0.48 suggests that a company does not have enough cash to cover immediate liabilities.

• Cash Turnover: -2.70

  Turnover Of Cash Ratio of -2.70 suggests that a company may have funds tied up in short-term low-yielding assets or may have a cash surplus, which is not invested in the business.

• Debt/Equity: 293.6%

  Debt to Equity Ratio of 293.6% suggests that greater risk assumed by creditors, hence greater interest by them in the way the company is being managed.

• Debt/FCF: -24.02

  Debt/FCF of -24.02 suggests that a company has a negative Free Cash Flow and probably will not be able to pay off its long term debt.

Efficiency Ratios

• Avg Collection Period: 53.37

  Average Collection Period of 53.37 days suggests that a company is doing well.

• Inventory Turnover: 2.12

  Inventory Turnover Ratio of 2.12 suggests a large inventory, a never-out-of-stock situation, perhaps some obsolete items, or it could indicate poor liquidity and possible overstocking of items.

• Profit Margin: -8.5%

PE and EPS

	Historical	Current	Forward
PE	-208.74	-1,000.00	35.45
EPS / Growth	16.5%	-0.01	43.8%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates	Pessimistic	Moderate	Optimistic	My Numbers
Rate of Return	15.0%
MOS Price %	50 %
Future EPS Growth	16.5%	36.8%	41.1%
Future PE	0.01	36.33	39.23
Future EPS	0.00	0.00	0.00
Value Price MOS	0.00 -100.0%	0.00 -100.0%	0.00 -100.0%
MOS Price	0.00	0.00	0.00
IRT	99.00	99.00	99.00

Graham Number:

Read more about Graham Number in Stock Market: Fundamental Analysis.

• Graham Number:
• Graham MOS: